---
schema_version: "secwatch.filing_event.v1"
accession: "0001439222-25-000114"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:18:21.217245+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Agios Q3 PYRUKYND rev $12.9M (+44% YoY); net loss $103.4M; thalassemia PDUFA Dec 7

## Summary
- Q3 PYRUKYND net revenue $12.9M (+44% YoY vs $9.0M); 149 U.S. patients on therapy.
- Net loss $103.4M in Q3 2025 vs net income $947.9M in Q3 2024 (prior-year milestone payments).
- Cash $1.3B; PDUFA goal date Dec 7, 2025 for PYRUKYND sNDA in thalassemia.
- CHMP positive opinion for PYRUKYND in thalassemia; EC decision expected early 2026.
- RISE UP Phase 3 sickle cell disease topline results by year-end; tebapivat Phase 2b topline early 2026.

## SEC filing metadata
- accession: 0001439222-25-000114
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000143922225000114/0001439222-25-000114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000143922225000114/agio-20251030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439222-25-000114
- JSON: https://secwatch.observer/filing/0001439222-25-000114.json
- Plain text: https://secwatch.observer/filing/0001439222-25-000114.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.